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Abstract
Background: Individual malaria interventions provide only partial protection in most epidemiological situations.
Thus, there is a need to investigate whether combining interventions provides added benefit in reducing mortality
and morbidity from malaria. The potential benefits of combining IPT in children (IPTc) with home management of
malaria (HMM) was investigated.
Methods: During the 2008 malaria transmission season, 1,277 children under five years of age resident in villages
within the rural Farafenni demographic surveillance system (DSS) in North Bank Region, The Gambia were
randomized to receive monthly IPTc with a single dose of sulphadoxine/pyrimethamine (SP) plus three doses of
amodiaquine (AQ) or SP and AQ placebos given by village health workers (VHWs) on three occasions during the
months of September, October and November, in a double-blind trial. Children in all study villages who developed
an acute febrile illness suggestive of malaria were treated by VHWs who had been taught how to manage malaria
with artemether-lumefantrine (Coartem™). The primary aims of the project were to determine whether IPTc added
significant benefit to HMM and whether VHWs could effectively combine the delivery of both interventions.
Results: The incidence of clinical attacks of malaria was very low in both study groups. The incidence rate of
malaria in children who received IPTc was 0.44 clinical attacks per 1,000 child months at risk while that for control
children was 1.32 per 1,000 child months at risk, a protective efficacy of 66% (95% CI -23% to 96%; p = 0.35). The
mean (standard deviation) haemoglobin concentration at the end of the malaria transmission season was similar in
the two treatment groups: 10.2 (1.6) g/dL in the IPTc group compared to 10.3 (1.5) g/dL in the placebo group.
Coverage with IPTc was high, with 94% of children receiving all three treatments during the study period.
Conclusion: Due to the very low incidence of malaria, no firm conclusion can be drawn on the added benefit of
IPTc in preventing clinical episodes of malaria among children who had access to HMM in The Gambia. However,
the study showed that VHWs can successfully combine provision of HMM with provision of IPTc.
Trial Registration: ClinicalTrials.gov NCT00944840
Background
Although the incidence of malaria appears to be declin-
ing in a number of African countries, it remains an
important cause of mortality and morbidity among
young children and pregnant women. Malaria control
strategies deployed in Africa include prompt treatment
of clinical attacks of malaria with an effective anti-
malarial drug combination, vector control using insecti-
cide-treated nets (ITNs) or curtains or indoor residual
spraying (IRS) and intermittent preventive treatment
(IPT). However, individually these interventions provide
only partial protection in most epidemiological situa-
tions [1]. Thus, there is a need to investigate whether
combining interventions provides added benefit in redu-
cing mortality and morbidity.
Studies have shown that IPT with sulphadoxine/
pyrimethamine (SP) given on two or three occasions
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during pregnancy provides significant protection
against maternal anaemia [2] and low birth weight [3],
especially in primigravidae and secundigravidae in
whom the risk of malaria is highest. These encoura-
ging results generated interest in the use of IPT for
the prevention of malaria and malaria-associated
severe anaemia in infants and children. IPT with SP
given at the time of routine infant immunization
(IPTi) reduces the incidence of malaria in the first
year of life by about 30% [4] and IPTi is now recom-
mended for introduction as a malaria control strategy
in countries where there is a significant burden of
malaria in infants and where SP resistance is low [5].
However, in many parts of Africa, in particular those
within the Sahelian and sub-Sahelian regions where
malaria transmission is seasonal, the main burden of
malaria is not in infants but in older children [6-8].
The potential for IPT to prevent malaria and anaemia
in children over the age of one year has been evalu-
ated in a limited number of trials carried out mainly
in West Africa. Results from these trials have indi-
cated that IPT in children aged one to five years
(IPTc) provided between 40% to 86% protection
against clinical attacks of malaria [9-11]. These results
suggest that IPTc has potential as an affordable
malaria and anaemia control measure.
Home-based management of malaria (HMM) is now
considered an important strategy for improving treat-
ment practices [12,13] and for reducing severe mor-
bidity and mortality from malaria in resource-poor
countries [14,15]. HMM involves presumptive treat-
ment of febrile children at or near home with anti-
malarial drugs distributed by trained members of the
community [16]. Community distributors provide
medications and educate primary caregivers about
treatment of malaria, administration of anti-malarial
drugs, and recognition of severe illness. A recent sys-
temic review concluded that the impact of HMM on
morbidity and mortality endpoints has been mixed
[17]. Two studies showed no health impact, while
another showed a decrease in malaria prevalence and
incidence, but no impact on mortality. One study in
Burkina Faso suggested that HMM decreased the pro-
portion of severe malaria cases, while another study
from the same country showed a decrease in the risk
of progression to severe malaria. Of the four studies
with mortality endpoints only one, from Ethiopia,
showed a positive impact, with a reduction in the
under-5 mortality rate of 40.6% (95% CI 29.2% -
50.6%) [17].
Although a number of trials of IPTc and HMM in chil-
dren, given as individual interventions, have been con-
ducted, only one trial has formally addressed the added
value of IPTc in children who have access to HMM. In
this study conducted in Ghana, IPTc with amodiaquine
and artesunate was given three times during the course
of the year to children aged 6 - 60 months who also had
access to HMM. The prevalence of malaria parasitaemia
was significantly lower at the end of the intervention
than at baseline but, as no control group was included in
the study, it is not possible to define the exact role played
by IPTc in achieving this improvement [18]. An addi-
tional placebo controlled trial to compare HMM with
Coartem™ combined with IPTc to HMM with Coartem™
alone in reducing morbidity from malaria in an area of
The Gambia with seasonal transmission of malaria has
been undertaken.
Methods
Study area and population
The study, based at the MRC Field Station, Farafernni in
the North Bank Region of The Gambia, was conducted
between May 2008 and January 2009. The trial was
undertaken in a group of 24 villages near Farafenni
which are part of the rural Farafenni demographic sur-
veillance system (DSS), described in detail elsewhere
[19]. There are 18 rural primary health care (PHC)
villages in the study area, two health centres and one
hospital in the study area. In PHC villages, village health
workers (VHWs) are given six to eight weeks of training
on how to treat common conditions such as uncompli-
cated malaria, acute respiratory infections, diarrhoeal
diseases and minor injuries. Since 2008, the first-line
treatment for uncomplicated malaria has been arte-
mether- lumefantrine (Coartem™, Novartis Pharma,
Basel Switzerland).
Malaria in The Gambia occurs almost exclusively
during the rainy season and immediately afterwards
(July to November) with peak transmission occurring
during October and November. The annual entomolo-
gical inoculation rate varies enormously across the
country and estimates have been reported in the range
of 1-177 [20].
Study design
The study was designed as a double-blind, randomized
placebo controlled trial. Children were individually ran-
domized to receive monthly treatment with a single
dose of SP plus three doses of amodiaquine (AQ) or SP
and AQ placebos from a VHW at monthly intervals on
three occasions during the months of September, Octo-
ber and November. All study children had ready access
to a VHW who had been trained to administer HMM
with Coartem™ to children who developed symptoms
compatible with malaria during the malaria transmission
season.
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Screening and enrolment
Prior to the start of the trial, meetings were held in all
potential study villages to explain the purpose and
methods of the study and to answer questions from
parents and guardians of eligible children. During
these meetings, agreement of a village to participate in
the study was obtained from the villagers. A list of
children living in the 24 villages, which agreed to join
the study who would be aged between six and 59
months at the time of the first treatment with IPTc in
September 2008 was obtained from the DSS database.
These children and their parents were invited for
screening for potential participation in the trial
between July and August 2008. Written informed con-
sent was obtained from parents or guardians of all
potentially eligible children before screening. The age
and identity of these children were checked, and they
were examined to rule out any clinically significant dis-
ease that might interfere with the outcome of the trial.
Children were considered eligible if they had no clini-
cally significant acute or chronic disease. Exclusion cri-
teria included known allergy to any anti-malarial drug
or the presence of acute or chronic, clinically signifi-
cant pulmonary, cardiovascular, hepatic or renal dis-
ease. A finger-prick blood sample was collected from
all children who met the inclusion criteria for prepara-
tion of a thick blood smear and measurement of hae-
moglobin (Hb) concentration. If a child had symptoms
suggestive of malaria, the blood film was examined
shortly after collection, whilst remaining blood films
were examined at a later date. Children with acute
malaria were treated with Coartem™ and excluded
from the study and those with anaemia were treated
with oral iron.
A reporter based in each village was asked to keep
records of all deaths, births and immigrations and emi-
grations that occurred during the study period. Village
reporters were visited fortnightly by a project field
worker and their records collected and checked. Deaths
were investigated using a modified version of the
INDEPTH post mortem questionnaire [21].
Randomization and drug distribution
One thousand two hundred and seventy-seven eligible
children whose parents consented were individually ran-
domized into either the SP plus AQ or placebo group in
a 1:1 ratio. The randomization list was generated using
permuted blocks of 12 by the trial statistician, using the
random number generator of STATA version 10. One
tablet of SP plus three tablets of AQ or one tablet of SP
placebo plus three tablets of AQ placebo were placed in
sealed opaque envelopes labelled with the randomization
number. For each study subject, a set of three envelopes
with the same randomization number, one for each
month were prepared. Each child enrolled was assigned
the next study number in sequence. Neither the VHWs
who administered the treatment, the field or laboratory
staff who collected data nor the families of study chil-
dren knew which was the active drug and which
placebo.
A recording system for drug administration that
could be used by VHWs, many of whom were illiter-
ate, was devised. This consisted of a treatment card
held by the mother or guardian of each child and an
IPT register held by the VHW. The treatment card
and the IPT register were labelled with the child’s,
mother’s and village’s names and compound, demo-
graphic surveillance and study numbers. The nature of
the treatment and the number of tablets of that treat-
ment that each child should receive was indicated on
the treatment card using a colour code to indicate the
treatment (white for SP or SP placebo and yellow for
AQ or AQ placebo) and full circles, half circles and
quarter circles to indicate the number of whole, half or
quarter tablets that the child should receive. Dosage
was based on the child ’s age. Children aged 3-11
months received half a tablet of SP or SP placebo and
a whole tablet was given to children aged 1-5 years.
One quarter, half or whole tablet of AQ or AQ pla-
cebo was given daily for three days to children aged 3-
11 months, 1-2 years and 3-5 years respectively. SP
tablets (500 mg sulphadoxine/25 mg pyrimethamine)
and amodiaquine (AQ) tablets (200 mg base tablets)
were obtained from Kina Pharma Ltd, Accra, Ghana
and their solubility and active drug content confirmed
at the London School of Hygiene and Tropical Medi-
cine. The first dose of treatment was given under
direct observation, the second and third doses by the
parent or guardian at home.
Morbidity surveillance during the rainy season
Passive surveillance for malaria was carried out during
the 2008 transmission season. Parents or guardians were
encouraged to take their child to the VHW at any time
their child became unwell. VHWs were instructed to
presumptively treat febrile illnesses suggestive of malaria
with Coartem™.
One field worker was attached to two to three
VHWs during the surveillance period. The role of the
field worker was to prepare a thick blood smear from
children who had been diagnosed as a case of malaria
by the VHW and scheduled for treatment with Coar-
tem™ for subsequent confirmation of the diagnosis.
Details of children treated by the VHWs were recorded
in books with help from field workers. VHWs referred
children who failed to improve on treatment and those
with danger signs (breathing difficulty, severe weak-
ness, convulsions, severe diarrhoea or vomiting) to the
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nearest health centre or to the AFPRC Hospital in Far-
afenni for further evaluation and management. Project
staff members were based at each of these health facil-
ities to identify children in the trial when they pre-
sented for treatment and to ensure that they were
properly investigated and treated promptly. At each
clinic visit, axillary temperature was recorded using a
digital thermometer and Hb concentration measured
using a Hemocue machine. A Rapid Diagnostic Test
for malaria (RDT) (Optimal, DiaMed AG, Cressier,
Switzerland) was done if a child had fever (axillary
temperature of ≥ 37.5°C) or a history of fever within
the previous 48 hours. In such cases, a thick blood
smear was also collected for subsequent confirmation
of the diagnosis. Children with documented fever (axil-
lary temperature of ≥ 37.5°C) or a history of recent
fever and malaria parasitaemia or a positive RDT were
treated with Coartem™. Children with severe malaria
were treated with intramuscular quinine. The treat-
ment of study subjects seen at the health centres for
conditions other than malaria was carried out in accor-
dance with national guidelines.
A cross-sectional survey of all available study children
was undertaken at the end of the malaria transmission
season. Children were examined by a project clinician
and anthropometric data were collected and a finger-
prick blood sample was obtained for preparation of thick
blood smears and determination of Hb concentration.
Laboratory methods
Thick smears were prepared in duplicate. If a child had
symptoms of malaria, one smear was stained with
Field’s stain and read promptly to guide treatment.
The other smear was stained with Giemsa and 200
high power fields (HPF) were examined before a smear
was declared negative. Only the Giemsa-stained slide
readings were used for the trial analysis. Parasite den-
sity was expressed per μl with the assumption that 1
parasite per high-powered field (hpf) equals a density
of 500 parasites per μl. All slides were read by two
laboratory technicians. If there was disagreement
between their readings on parasite positivity or if the
difference of the log-densities recorded was more than
1.5, slides were read by a third technician. Agreement
was reached among the three technicians after the
slides had been re-checked. When a laboratory techni-
cian was not immediately available to read a thick
blood smear the result of the RDT was used to guide
treatment, and a thick blood smear collected for subse-
quent confirmation of the diagnosis. Hb concentration
was measured at recruitment, during morbidity surveil-
lance and at the end of malaria transmission season
surveys using a portable haemoglobinometer (Hemo-
Cue AB, Sweden).
Data management
Data from participants were recorded on paper forms
and were checked by field supervisors, study physician,
and data manager for consistency and accuracy. All data
were entered twice into a SQL database using MS
Access software. The accuracy of data input was
checked and validated using customized validation pro-
grammes. The cleaned data were converted to STATA
version 10 file (STATA Corporation, Texas, USA) prior
to analysis.
Statistical analysis
The primary study endpoint was the incidence of clini-
cal malaria (documented fever [axillary temp ≥ 37.5°C]
or a history of fever within the previous 48 hours
accompanied by asexual malaria parasitaemia at a den-
sity of ≥5,000 parasites/μL) among study subjects seen
at one of the health centres or at the district hospital
during the surveillance period. Secondary endpoints
included incidence of a febrile illness with parasitaemia
at any density among children seen by a VHW or at a
health centre or hospital, incidence of anaemia among
children seen at a health centre or hospital, the preva-
lence of parasitaemia at the end of malaria transmis-
sion season cross-sectional survey, the prevalence of
anaemia at the end of malaria transmission season
cross-sectional survey, the proportion of children who
received three IPTc treatment courses and the propor-
tion of children who received no IPTc treatment
course.
The incidence of malaria seen at a health centre or
hospital in children who had access to HMM and who
received placebo was estimated to be 0.2 episodes per
child per transmission season. To detect a 40% reduc-
tion in the incidence of malaria with a power of 90%,
using a significance level of 5% and assuming 20% loss
to follow-up in children who received IPTc, 625 chil-
dren per group were needed. For the cross-sectional
survey, assuming a parasite prevalence of 20% at the
end of transmission season in children who had access
to HMM and received placebo, 557 children in each
study group were needed to show a 40% reduction in
the prevalence of malaria in children who received
IPTc in addition to HMM with 90% power at the 5%
level of significance assuming a 20% loss to follow-up.
A reporting and analysis plan (RAP) was developed
prior to breaking the code. The primary analysis
included all children who were randomized, regardless
of the number of treatments received. Characteristics
of all children enrolled in the study were tabulated by
study arm. For the primary outcome of malaria inci-
dence during the study period, analysis was by inten-
tion to treat. Time at risk was calculated from date of
enrolment until the date of cross-sectional survey or
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until date of death or emigration from the study area
with no return. No child had more than one episode
of malaria so no adjustment for clustering was
required. The protective effect of IPTc in addition to
HMM against malaria during the surveillance period
was calculated as 100(1-R), where R is the incidence
rate ratio for the IPTc versus the placebo group, calcu-
lated using Cox regression. The effects of IPTc on
incidence of anaemia and other complaints were calcu-
lated in the same way.
Prevalences of anaemia and parasitaemia in the
cross-sectional survey at the end of the malaria trans-
mission season were compared between the two
groups using logistic regression. Hb concentrations at
the end of the transmission season were compared
using linear regression, adjusting for Hb at enrolment.
Coverage with IPTc was evaluated from records kept
by VHWs of treatment administration. The propor-
tions of children who had received each monthly treat-
ment course, those who received three treatment
courses, and those who received no treatment were
tabulated.
Ethical review
The study was approved by the London School of
Hygiene & Tropical Medicine Ethics Committee and by
the joint MRC/Gambia Government Ethics Committee.
Results
Baseline characteristics
One thousand three hundred and thirty-four children
aged 6-59 months were selected from the Farafenni
DSS and screened; 1,277 children who met the entry
criteria were enrolled and allocated to receive
monthly IPT with SP plus AQ (639) or SP placebo
plus AQ placebo (638). The remaining 57 were not
enrolled because they did not meet the inclusion cri-
teria, no consent was given or because they had one
of the exclusion criteria (Figure 1). At enrolment, the
two treatment groups were similar with respect to
baseline features such as age, ethnic group and mean
Hb concentration (Table 1). Plasmodium falciparum
parasitaemia was found infrequently at enrolment;
only 0.5% of study subjects in either treatment group
had parasitaemia; 93% of the study subjects slept
under an ITN.
Coverage with IPTc
Table 2 shows the number of children who came
for their scheduled monthly treatment during the
malaria transmission period. A high rate of cover-
age was achieved throughout the trial. Among the
1277 study subjects enrolled in the study, 98.8% in
each group received treatment 1, 96.1% and 96.7%
in the SP/AQ and the control groups respectively
received treatment 2, and 95.3% and 96.2% in the
SP/AQ and placebo groups respectively received
treatment 3. The most common reasons for missing
a dose were travelling out of the study area or par-
ental refusal.
Impact of the interventions on morbidity from malaria
and on anaemia
The incidence of clinical attacks of malaria was very
low in each treatment group; no child had more than
one episode of malaria. There were no cases of malaria
with parasitaemia at a density of ≥5,000 parasites/μL.
Table 3 shows the number of malaria episodes with
any parasitaemia detected during the study among
children attending a health centre or hospital, and
among children seen by a VHW. During the malaria
transmission season only one clinical episode of
malaria was recorded at a health centre in children
who received SP plus AQ and only two episodes in
children who received placebo. One additional episode
was detected by a VHW in a child in the placebo
group. The incidence rate of malaria detected by any
means in children who received the intervention was
0.44 per 1,000 child months at risk while that for con-
trol children was 1.32 per 1000 child months at risk,
giving a protective efficacy of 66% (95% CI -228% to
96%; p = 0.35). There were no differences in incidence
of anaemia or other morbidity indicators during the
surveillance period (Table 4).
One thousand and forty-six study children (513
SP/AQ, 533 placebo) were seen at the end of the
malaria transmission season. Three (0.67%) children in
the SP/AQ group had asexual stage P. falciparum
parasitaemia compared with 5 (0.9%) in the control
group (p = 0.73). The prevalence of splenomegaly at
the end of malaria transmission season was also very
low in the two groups (2.0% SP/AQ vs 3.0% placebo;
p = 0.29). The proportions of children with a Hb con-
centration of < 8 g/dL at the end of the malaria trans-
mission season were similar in the two groups of
children, 44/513(8.6%) in children who received SP/AQ
and 45/533 (8.4%) in those who received placebo (OR
adjusted for baseline Hb 0.81, 95% CI 0.48, 1.36; P =
0.41). The mean (standard deviation) Hb concentration
at the end of the malaria transmission season was
similar in the two treatment groups; 10.2 (1.6) g/dL in
the SP/AQ group compared to 10.3 (1.5) in the pla-
cebo group, difference adjusted for baseline Hb 0.04
(95% CI -0.09, 0.17; P = 0.55).
Safety of IPTc with SP/AQ
There was only one death during the surveillance period
among the 1,277 study children. This child, who was in
Sesay et al. Malaria Journal 2011, 10:2
http://www.malariajournal.com/content/10/1/2
Page 5 of 9
* The remaining children were not studied because they did not meet  the inclusion criteria, 
no consent was given  or  had one  of the exclusion criteria 
Figure 1 Trial profile. * The remaining children were not studied because they did not meet the inclusion criteria, no consent was given or
had one of the exclusion criteria.
Table 1 Enrolment characteristics of children in the two
study groups
Intervention group
Variable Placebo
(n = 638)
SP/AQ
(n = 639)
Age (months) (mean, SE) 29.9 (16.5) 30.1 (17.3)
Sex (% male) 323 (51.4%) 309 (49.6%)
Sleep nightly under impregnated bed net 596 (93.3%) 596 (93.3%)
Ethnic group
Fula 241 (38.0%) 238 (38.0%)
Mandingo 73 (11.5%) 63 (10.1%)
Wollof 311 (49.0%) 316 (50.5%)
Other 20 (1.6%) 9 (1.4%)
Mean haemoglobin g/dl 10.2 (1.4) 10.1 (1.5)
Splenomegaly 16 (3.0%) 18 (3.4%)
Malaria parasitaemia 3 (0.5%) 3 (0.5%)h
Table 2 Number of treatment courses of trial medication
received
Treatment round Outcome Placebo SP/AQ
Treatment 1 (September) Received 637 (99.8%) 638 (99.8%)
Refused 0 0
Absent 1 (0.2%) 1 (0.2%)
Treatment 2 (October) Received 617 (96.7%) 614 (96.1%)
Refused 7 (1.1%) 8 (1.3%)
Absent 14 (2.2%) 17 (2.7%)
Treatment 3 (November) Received 614 (96.2%) 609 (95.3%)
Refused 9 (1.4%) 13 (2.0%)
Absent 15 (2.4%) 17 (2.7%)
Overall treatment coverage p-value
% with 3 treatments 604 (94.7%) 597 (93.4%) 0.35
% with 0 treatments 1 (0.2%) 1 (0.2%) 1.00
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the placebo group, died at home in December; a verbal
autopsy suggested a diagnosis of pneumonia. Fourteen
children were admitted to one of the health facilities in the
study area during the surveillance period, two of them
twice. The 16 admissions were equally distributed between
treatment arms, nine children were diagnosed with pneu-
monia (five and four in the intervention and control
groups, respectively) and with acute gastroenteritis (2 and
1 in the intervention and control groups respectively).
Remaining admissions were for anaemia, malnutrition,
upper respiratory tract infection and severe helminth
infection. One child in the SP/AQ group developed a drug
eruption which presented as multiple areas of macular
hyperpigmentation of different sizes mainly on the trunk
with sharply demarcated outlines.
Discussion
This study was carried out to determine whether IPTc
with SP plus AQ provided additional benefit in reducing
malaria morbidity in children who received HMM in
the context of high ITN coverage. Very few cases of
malaria were detected in either arm of the trial so the
study was not able to determine its primary objective. In
addition, IPTc with SP plus AQ did not have any mea-
surable impact on anaemia or splenomegaly.
The very low incidence of malaria encountered in
the Farafenni area of The Gambia was surprising but
consistent with other recent data from The Gambia
that have indicated a dramatic fall in the incidence of
malaria in The Gambia in recent years [8]. Why such
a dramatic decline in malaria incidence has occurred
over a relatively short period of time is not clear.
Improvements in overall living and educational stan-
dards, a change of first line treatment from ineffec-
tive chloroquine to SP and then to artemisinin
combination therapy (ACT) and scaling up of the
distribution of ITNs (coverage of ITN among the
study population was about 93%) are all likely to
have played a part.
In recent years, significant reductions in the inci-
dence of malaria have been reported in several coun-
tries in Africa where malaria was previously
moderately endemic [22]. This success in malaria con-
trol has led to a renewed interest in the possibility of
national or regional elimination of malaria in endemic
areas with the ultimate goal of eradicating the infec-
tion. Malaria elimination will require the use of combi-
nation of interventions and results from this trial
highlights the importance of conducting research to
determine how combinations of interventions can be
used most effectively at different stages of elimination.
This trial showed that in an area with seasonal trans-
mission, a currently low incidence of malaria and with
high ITN coverage, IPTc did not provide any
Table 3 Frequency of malaria during the study
Outcome Placebo SP/AQ Protective efficacy
(95% CI)
P
value
Events Person
months at risk
Incidence rate/1000
person months
Event Person
months at risk
Incidence
Rate/1000
person months
Clinical malaria,
diagnosed at OPD
2 2279 0.88 1 2248 0.44 49% (-468%, 95%) 0.59
Clinical malaria,
diagnosed at OPD
or by VHW
3 2279 1.32 1 2248 0.44 66% (-228%, 96%) 0.35
Table 4 Morbidity in children who received SP plus AQ or placebo during the malaria transmission period
Placebo (person months at risk, 2279) SP/AQ (person months at risk, 2248)
Outcome Events Incidence rate/
100 person months
Events Incidence rate/
100 person months
Protective
efficacy
(95% CI)
P
Total outpatient visits 142 6.2 155 6.9 -11% (-42%, 14%) 0.42
Anaemia (Hb < 11 g/dL) 71 3.1 70 3.1 0% (-44%, 30%) 0.99
Moderate anaemia
(Hb < 8 g/dL)
14 0.6 13 0.6 6% (-100%, 60%) 0.89
Fever (temp ≥ 37.5°C) 33 1.4 28 1.2 14% (-42%, 48%) 0.55
Upper respiratory tract infection 48 2.1 49 2.2 -4% (-58%, 32%) 0.86
Skin/soft tissue infection 25 1.1 21 0.9 15% (-53%, 47%) 0.59
Gastroenteritis 42 1.8 39 1.7 6% (-60%, 45%) 0.83
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additional benefit to HMM. However, this might not
be the case in other areas where much higher levels of
seasonal malaria have persisted, such as parts of Bur-
kina Faso and Mali.
No serious adverse events which could be directly
attributed to the study medication were observed. One
skin rash was observed but this did not have features of
Stevens Johnson syndrome.
IPTc would not be a useful intervention in The
Gambia if the incidence of malaria persists at its
currently very low level. However, recent studies in
Burkina Faso and Mali [23,24] have demonstrated that
IPTc with the same drug combination used in this trial
reduced the incidence of uncomplicated and severe
malaria by 70-80% in children who slept under an
ITN. In such epidemiological situations, IPTc may
prove to be a very valuable intervention if an effective
method of drug delivery can be achieved. In this study
we have shown how VHWs can be trained to deliver
both IPTc and HMM effectively and how high cover-
age levels with IPTc can be achieved. A simple delivery
system that can be used by community health workers
with little training, some of whom were illiterate, was
devised. This approach to malaria control needs to be
re-evaluated in other areas where malaria transmission
remains high and where IPTc could have a major
impact.
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